$275 Million is the total value of RTW INVESTMENTS, LP's 34 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 37.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $54,383,000 | +0.8% | 866,379 | +51.1% | 19.74% | +10.7% |
| INCY | New | Incyte Corp | $27,496,000 | – | 379,415 | +100.0% | 9.98% | – |
| LJPC | Buy | La Jolla Pharmaceutical Co | $24,445,000 | -16.5% | 1,169,065 | +7.8% | 8.88% | -8.2% |
| ACHN | Buy | Achillion Pharmaceuticals Inc | $19,754,000 | -7.9% | 2,558,859 | +28.7% | 7.17% | +1.2% |
| KITE | Sell | Kite Pharma Inc | $15,770,000 | -38.9% | 343,503 | -18.0% | 5.72% | -32.9% |
| OMER | Sell | Omeros Corp | $13,676,000 | -52.2% | 891,522 | -51.0% | 4.96% | -47.5% |
| AVXS | New | Avexis Inc | $12,895,000 | – | 473,374 | +100.0% | 4.68% | – |
| DRNA | Buy | Dicerna Pharmaceuticals Inc | $10,864,000 | -54.5% | 2,026,894 | +0.7% | 3.94% | -50.0% |
| AGEN | Buy | Agenus Inc | $10,044,000 | -0.1% | 2,414,524 | +9.0% | 3.65% | +9.8% |
| BLUE | New | bluebird bio Inc | $9,621,000 | – | 226,371 | +100.0% | 3.49% | – |
| FPRX | Sell | Five Prime Therapeutics Inc | $9,223,000 | -13.6% | 226,998 | -11.8% | 3.35% | -5.0% |
| MRTX | Buy | Mirati Therapeutics Inc | $9,169,000 | -24.7% | 428,457 | +11.2% | 3.33% | -17.3% |
| SSRG | Buy | Symmetry Surgical Inc | $9,068,000 | +12.0% | 919,680 | +4.6% | 3.29% | +23.2% |
| ATRA | Buy | Atara Biotherapeutics Inc. | $9,004,000 | -21.4% | 473,126 | +9.0% | 3.27% | -13.6% |
| BMY | Bristol-Myers Squibb Co | $7,008,000 | -7.1% | 109,701 | 0.0% | 2.54% | +2.1% | |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $5,586,000 | -73.1% | 1,973,932 | -1.8% | 2.03% | -70.4% |
| TLT | New | iShares 20+ Year Treasury Bond ETF20 yr tr bd etf | $3,918,000 | – | 30,000 | +100.0% | 1.42% | – |
| CLDX | Buy | Celldex Therapeutics Inc | $3,740,000 | -62.6% | 989,376 | +55.3% | 1.36% | -58.8% |
| CORI | Buy | Corium International Inc | $3,197,000 | -47.1% | 828,332 | +11.4% | 1.16% | -41.8% |
| GBT | Buy | Global Blood Therapeutics Inc | $3,029,000 | -46.5% | 190,981 | +9.0% | 1.10% | -41.2% |
| RGNX | Buy | Regenxbio Inc | $2,606,000 | -29.1% | 241,323 | +9.0% | 0.95% | -22.1% |
| LPCN | Buy | Lipocine Inc | $2,440,000 | -14.4% | 240,438 | +9.0% | 0.89% | -5.9% |
| AXDX | Buy | Accelerate Diagnostics Inc | $1,684,000 | -27.1% | 117,176 | +9.0% | 0.61% | -19.9% |
| IVTY | Buy | Invuity Inc | $1,536,000 | -14.1% | 212,808 | +4.9% | 0.56% | -5.6% |
| CYTR | Buy | CytRx Corp | $1,375,000 | +10.3% | 513,092 | +9.0% | 0.50% | +21.1% |
| MASI | New | Masimo Corp | $1,084,000 | – | 25,900 | +100.0% | 0.39% | – |
| MNKD | New | MNKD 01/20/2017 PUT 3put | $899,000 | – | 4,385 | +100.0% | 0.33% | – |
| BPMX | Buy | Biopharmx Corp | $764,000 | +35.7% | 700,636 | +89.0% | 0.28% | +48.9% |
| MDRX | New | Allscripts Healthcare Solutions Inc | $634,000 | – | 48,000 | +100.0% | 0.23% | – |
| NTRA | New | Natera Inc | $302,000 | – | 31,693 | +100.0% | 0.11% | – |
| NVLS | Nivalis Therapeutics Inc | $125,000 | -46.1% | 30,000 | 0.0% | 0.04% | -41.6% | |
| ADAP | Buy | Adaptimmune Therapeutics-adrsponds adr | $63,000 | -25.9% | 7,691 | +9.0% | 0.02% | -17.9% |
| NVRO | NVRO 05/20/2016 PUT 50put | $36,000 | -2.7% | 142 | 0.0% | 0.01% | +8.3% | |
| BRKB | Berkshire Hathaway Inccl b new | $7,000 | 0.0% | 50 | 0.0% | 0.00% | +50.0% | |
| USO | Exit | USO 01/15/2016 CALL 25call | $0 | – | -13,850 | -100.0% | -0.00% | – |
| VIVO | Exit | VIVO 01/15/2016 CALL 20call | $0 | – | -1,252 | -100.0% | -0.04% | – |
| DYAX | Exit | Dyax Corp | $0 | – | -115,795 | -100.0% | -1.44% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.